Cleveland HeartLab LLC has added a test of low-density lipoprotein, the so-called “bad cholesterol,” to its portfolio of heart-inflammation tests.
The company’s NMR LipoProfile test measures and counts LDL particles, which carry cholesterol in the blood and can build up on artery walls, leading to atherosclerosis and cardiovascular disease.The higher the LDL particle level, the higher the risk of heart attack.
LDL-particle measurement is an important tool for the assessment and ongoing management of cardiovascular disease risk, according to a statement from Cleveland HeartLab.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company is a clinical reference laboratory specializing in cardiovascular disease prevention, diagnosis and management. Cleveland HeartLab is developing tests for inflammation biomarkers based on research licensed from the Cleveland Clinic. It already has one Food and Drug Administration-approved test that detects an enzyme called myeloperoxidase, or MPO, in the blood. Certain levels of MPO can identify people who are at risk for heart attack, stroke or death.
In March, the company completed a $3 million fundraising round.
